Aptevo Files Patent for Nectin-4 x PD-L1 Dual-Targeting Backbone to Expand Solid Tumor Strategy
核心洞察
Aptevo Therapeutics has filed a patent application for a proprietary Nectin-4 (搜索) x PD-L1 (搜索) dual-targeting backbone designed to support multiple therapeutic modalities including radiopharmaceuticals and T-cell engagers.
The dual-targeting approach aims to improve tumor localization by binding both Nectin-4 (搜索), found on several solid tumors, and PD-L1 (搜索), present on tumor cells and immune-suppressing cells within the tumor microenvironment.
The versatile backbone leverages Aptevo's ADAPTIR and ADAPTIR-FLEX platforms and is intended to expand the company's pipeline, create partnering opportunities, and address the complexity of difficult-to-treat solid tumors.
Aptevo Therapeutics Inc. (NASDAQ:APVO) has filed a patent application covering a proprietary Nectin-4 (搜索) x PD-L1 (搜索) dual-targeting backbone, a move the clinical-stage biotechnology company describes as foundational to a broader solid tumor strategy designed to fight cancer on multiple fronts. The filing, announced July 27, 2026, is intended to protect a versatile targeting architecture that may be adapted into radiopharmaceuticals, T-cell engagers, and other immune-modulating therapies.
"This filing is about building value from our science and using it to create more ways to fight solid tumors," said Jeff Lamothe, President and Chief Executive Officer of Aptevo. "Aptevo has built a reusable targeting architecture that can generate multiple assets, support multiple therapeutic approaches and create multiple paths to value."
Dual-Targeting Rationale
The backbone is engineered to recognize two clinically validated targets in solid tumors: Nectin-4 (搜索), a tumor-associated marker expressed on several solid tumor types, and PD-L1 (搜索), which is found both on tumor cells and on immune-suppressing cells within the tumor microenvironment. By targeting both antigens simultaneously, Aptevo aims to direct therapeutic activity more selectively to tumor sites while better avoiding normal tissues compared with single-targeted agents.
"What excites us scientifically is the versatility of this backbone," said Mary Janatpour, Ph.D., Chief Scientific Officer of Aptevo. "We designed it to recognize two important targets in solid tumors, Nectin-4 (搜索) and PD-L1 (搜索), and to give us a foundation we can build on in multiple ways."
In addition to enhanced tumor localization, targeting PD-L1 (搜索) on immune-suppressing cells is intended to enhance anti-tumor immunity. The company notes that from this foundation, additional functional components can be incorporated to deepen anti-tumor efficacy.
Platform Versatility and Strategic Applications
The Nectin-4 (搜索) x PD-L1 (搜索) backbone demonstrates the utility of Aptevo's proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, which allow the company to adjust construct design and incorporate different therapeutic components depending on the intended application. The same targeting concept may be used to create distinct therapeutic modalities for hard-to-treat solid tumors.
Radiopharmaceutical therapy represents one potential application and an area of growing focus for Aptevo. Pairing tumor-targeting constructs with radioligands could support the development of targeted radiopharmaceutical candidates designed to deliver treatment activity directly to tumors. The backbone may also support T-cell engagers and other immune-based therapies, providing multiple avenues to pursue solid tumors through tumor targeting, immune activation, and payload delivery.
The filing strengthens Aptevo's intellectual property portfolio and supports a platform-driven strategy: using proprietary science to create multiple shots on goal, retain strategic control, and open the door to collaborations that could accelerate development.
Building on Nectin-4 (搜索) Expertise
The patent filing builds on Aptevo's existing investment in nectin-4 (搜索)-targeted therapies. In June 2026, the company was awarded a $1.5 million non-dilutive research grant from the Andy Hill Cancer Research Endowment (CARE) Fund to support IND-enabling work for APVO451 (搜索), a novel trispecific antibody-like immunotherapy candidate targeting nectin-4 for solid tumors.
APVO451 (搜索) brings together three functions in a single molecule: targeting nectin-4 (搜索), activating CD40 (搜索) on antigen-presenting cells to engage innate immunity, and engaging CD3 (搜索) on T-cells to direct tumor-cell killing. The trispecific candidate is designed so that its CD3 and CD40 activity depends on binding to nectin-4, helping focus immune activation within the tumor microenvironment and reduce the risk of systemic immune activation.
"By combining nectin-4 (搜索)-targeting with CD40 (搜索) and CD3 (搜索) engagement, APVO451 (搜索) is designed to activate both antigen-presenting cells and T cells within the tumor microenvironment," said Janatpour. APVO451 is advancing toward development candidate selection by year-end 2026, with IND-enabling studies anticipated to begin in the first quarter of 2027.
The dual-targeting backbone and the APVO451 (搜索) trispecific program together reflect Aptevo's broader effort to extend its controlled immune-activation platform into solid tumors, an area where the tumor microenvironment continues to present significant challenges for immunotherapy.